Orally disintegrating tablets containing famotidine nanoparticles provide high intestinal absorbability via the energy-dependent endocytosis pathway

The permeability of the Biopharmaceutics Classification System (BCS) class III drugs are low, and their oral bioavailability needs to be improved. In this study, we attempted to design oral formulations containing famotidine (FAM) nanoparticles to overcome the limitations of BCS class III drugs. Dispersions containing FAM nanoparticles with a particle size of approximately 50–220 nm were produced by the bead-milling treatment. Moreover, we succeeded in preparing an orally disintegrating tablet containing FAM nanoparticles using the dispersions described above, additives (D-mannitol, polyvinylpyrrolidone, and gum arabic), and freeze-dry treatment (FAM-NP tablet). The FAM-NP tablet was disaggregated 3.5 s after addition to purified water, and the FAM particles in the redispersion of the FAM-NP tablet stored for 3 months were nano-sized (141 ± 6.6 nm). The ex-vivo intestinal penetration and in vivo absorption of FAM in rats applied with the FAM-NP tablet were significantly higher than those in rats applied with the FAM tablet containing microparticles. In addition, enhanced intestinal penetration of the FAM-NP tablet was attenuated by an inhibitor of clathrin-mediated endocytosis. In conclusion, the orally disintegrating tablet containing FAM nanoparticles improved low mucosal permeability and low oral bioavailability and overcame these issues of BCS class III drugs as oral formulations.

[1]  F. Ogata,et al.  Oral Formulation Based on Irbesartan Nanocrystals Improve Drug Solubility, Absorbability, and Efficacy , 2022, Pharmaceutics.

[2]  F. Ogata,et al.  Nanocrystalline Suspensions of Irbesartan Enhance Oral Bioavailability by Improving Drug Solubility and Leading Endocytosis Uptake into the Intestine , 2021, Pharmaceutics.

[3]  F. Ogata,et al.  Fixed-Combination Eye Drops Based on Fluorometholone Nanoparticles and Bromfenac/Levofloxacin Solution Improve Drug Corneal Penetration , 2021, International journal of nanomedicine.

[4]  F. Ogata,et al.  Oral Administration System Based on Meloxicam Nanocrystals: Decreased Dose Due to High Bioavailability Attenuates Risk of Gastrointestinal Side Effects , 2020, Pharmaceutics.

[5]  J. Huwyler,et al.  Mechanisms of increased bioavailability through amorphous solid dispersions: a review , 2019, Drug delivery.

[6]  Yoshihiro Oaku,et al.  Drug Delivery System Based On Minoxidil Nanoparticles Promotes Hair Growth In C57BL/6 Mice , 2019, International journal of nanomedicine.

[7]  F. Ogata,et al.  Energy-dependent endocytosis is responsible for drug transcorneal penetration following the instillation of ophthalmic formulations containing indomethacin nanoparticles , 2019, International journal of nanomedicine.

[8]  H. Byrne,et al.  Cold Atmospheric Plasma Induces ATP-Dependent Endocytosis of Nanoparticles and Synergistic U373MG Cancer Cell Death , 2018, Scientific Reports.

[9]  Bazigha K. Abdul Rasool,et al.  Optimized Mucoadhesive Coated Niosomes as a Sustained Oral Delivery System of Famotidine , 2017, AAPS PharmSciTech.

[10]  D. Harinarayana,et al.  In Vitro Intestinal Permeability Studies and Pharmacokinetic Evaluation of Famotidine Microemulsion for Oral Delivery , 2014, International scholarly research notices.

[11]  Zhihong Zhu,et al.  Controlled delivery of carvedilol nanosuspension from osmotic pump capsule: in vitro and in vivo evaluation. , 2014, International journal of pharmaceutics.

[12]  E. Nikolsky,et al.  The effect of dynasore, a blocker of dynamin-dependent endocytosis, on spontaneous quantal and non-quantal release of acetylcholine in murine neuromuscular junctions , 2014, Doklady Biological Sciences.

[13]  Jie Shen,et al.  Nano-amorphous spray dried powder to improve oral bioavailability of itraconazole. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[14]  S Kumar,et al.  Wet milling induced physical and chemical instabilities of naproxen nano-crystalline suspensions. , 2014, International journal of pharmaceutics.

[15]  Y. Shimomura,et al.  A nanoparticle formulation reduces the corneal toxicity of indomethacin eye drops and enhances its corneal permeability. , 2014, Toxicology.

[16]  J. Patel,et al.  Design and evaluation of famotidine mucoadhesive nanoparticles for aspirin induced ulcer treatment , 2013 .

[17]  Hywel D Williams,et al.  Strategies to Address Low Drug Solubility in Discovery and Development , 2013, Pharmacological Reviews.

[18]  Imre Mäger,et al.  The role of endocytosis on the uptake kinetics of luciferin-conjugated cell-penetrating peptides. , 2012, Biochimica et biophysica acta.

[19]  K. Tochigi,et al.  Determination and correlation of solubilities of famotidine in water + co-solvent mixed solvents , 2011 .

[20]  M. Dhanaraju,et al.  Evaluation of Gastric and Duodenal Antiulcer Activityof Ranitidine Formulation in Experimental Animals , 2011 .

[21]  Shan Ren,et al.  New perspectives on lipid and surfactant based drug delivery systems for oral delivery of poorly soluble drugs , 2010, The Journal of pharmacy and pharmacology.

[22]  F. Hirayama,et al.  Evaluation of carboxymethyl-beta-cyclodextrin with acid function: improvement of chemical stability, oral bioavailability and bitter taste of famotidine. , 2010, International journal of pharmaceutics.

[23]  F. Hollfelder,et al.  Fluid phase endocytosis contributes to transfection of DNA by PEI-25. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[24]  M. Kassem,et al.  Enhancement of famotidine dissolution rate through liquisolid tablets formulation: in vitro and in vivo evaluation. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[25]  S. Stainmesse,et al.  Freeze-drying of nanoparticles: formulation, process and storage considerations. , 2006, Advanced drug delivery reviews.

[26]  P. Malfertheiner,et al.  Peptic ulcer disease , 2002, The Lancet.

[27]  R. Hunt,et al.  Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician. , 2001, Best practice & research. Clinical gastroenterology.

[28]  Mohammad A. Hassan,et al.  Improvement of the in vitro dissolution characteristics of famotidine by inclusion in β-cyclodextrin , 1990 .

[29]  D. T. Lyon.  Efficacy and safety of famotidine in the management of benign gastric ulcers. , 1986, The American journal of medicine.

[30]  Diane J Burgess,et al.  Pharmaceutical Amorphous Nanoparticles. , 2017, Journal of pharmaceutical sciences.